• argenx floated on Euronext Brussels with an initial market capitalisation of €132m
• Proceeds of the IPO will be used to advance the clinical development of differentiated therapeutic antibody candidates
• Kempen & Co acted as Joint Global Coordinator and Joint Bookrunner and placed the majority of shares with long only specialist investors